Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enhertu plus chemotherapy with or without pembrolizumab versus trastuzumab plus chemotherapy with or without pembrolizumab in first-line metastatic HER2-positive gastric or GEJ cancer
NL-OMON60548Phase 3Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jun 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of trastuzumab deruxtecan in gastric cancer (GC) and gastroesophageal junction adenocarcinoma (4 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Progression-free survival by blinded independent central review. Started Jun 2025; status: recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NL-OMON60548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60548.